Sarepta: Broad Label Expansion Possible With Q4 2023 Catalyst NASDAQ:SRPT

According to analysts, Sarepta Therapeutics’s stock has a predicted upside of 36.80% based on their 12-month price targets. What’s even more important is that Sarepta is demonstrating its ability to develop novel therapies for difficult-to-treat diseases. And its pipeline features other candidates that target this disease. Sarepta Therapeutics may not yet be profitable, but the company looks like a rising …

Continue Reading
Open chat
Hello
Can we help you?